{"entity":{"id":"nct05607550","kind":"trial","name":"Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With","aka":["FURVENT"],"tldr":"A phase 3 trial of Furmonertinib in non-small-cell lung cancer and small-cell lung cancer, run by ArriVent BioPharma, Inc., active and no longer recruiting.","summary":"Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) is a phase 3 interventional study registered as NCT05607550 by ArriVent BioPharma, Inc., with 398 participants enrolled, started 2023-06-01 and due to reach its primary completion in 2025-08-15. Interventions recorded: furmonertinib 240 mg oral, daily, furmonertinib 160 mg oral, daily, platinum-based chemotherapy. Conditions listed: Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05607550","url":"https://clinicaltrials.gov/study/NCT05607550"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","egfr-mutant-nsclc"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["furmonertinib"],"companies":["arrivent"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05607550","phase":"3","setting":"A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)","sponsor":"ArriVent BioPharma, Inc.","participation":[{"nct":"NCT05607550","source":"https://clinicaltrials.gov/study/NCT05607550","fetchedAt":"2026-10-07T16:53:47.239Z","studySha256":"f5ec6e044d1b71270b21194fcb906f7d654e4ffdab1ef3f62581427f42b5ebb3","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2025-06-22","leadSponsor":"ArriVent BioPharma, Inc.","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":398,"enrolmentType":"ACTUAL","siteCount":208,"recruitingSiteCount":0,"countries":["Australia","Brazil","Canada","China","France","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","Philippines","Singapore","South Korea","Spain","Taiwan","Thailand","United Kingdom","United States"]}],"started":"2023-06-01","startedType":"actual","enrolled":398,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05607550/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"furmonertinib","kind":"drug","name":"Furmonertinib","route":"/drugs/furmonertinib/"}],"company":[{"id":"arrivent","kind":"company","name":"ArriVent BioPharma","route":"/companies/arrivent/"}]}}